<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1442">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01753323</url>
  </required_header>
  <id_info>
    <org_study_id>CKAF156X2201</org_study_id>
    <nct_id>NCT01753323</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection</brief_title>
  <official_title>A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Thailand: Institute for Development of Human Research Protection (IHRP)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria
      patients with P. vivax or P. falciparum infection after 3 day dosing with KAF156 at 400
      mg/day (Part 1) and single dosing with KAF156 at 800mg (Part 2)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to Parasite Clearance</measure>
    <time_frame>Day 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Parasite clearance was determined by assessing the parasite count in blood, using thin film, thick film and blood density assessments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>28-day Cure Rate - Part 2</measure>
    <time_frame>Day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>28-day cure rate was defined as the percentage of participants with blood parasite count of zero after 28 days of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)0-24h - Part 1</measure>
    <time_frame>Days 1 and 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC0-24h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose was taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) - Part 1</measure>
    <time_frame>Days 1 and 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) - Part 1</measure>
    <time_frame>Days 1 and 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)Last - Part 1</measure>
    <time_frame>Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUClast was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)Inf - Part 1</measure>
    <time_frame>Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUCinf was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) - Part 1</measure>
    <time_frame>Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>T1/2 was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL/F ) - Part 1</measure>
    <time_frame>Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>CL/F was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F) - Part 1</measure>
    <time_frame>Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vz/F was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio (Racc) (=AUC0-24h, day3/AUC0-24h, day1) - Part 1</measure>
    <time_frame>Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Racc was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24h - Part 2</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC0-24h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-48h - Part 2</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC0-48h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast - Part 2</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUClast was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf - Part 2</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUCinf was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax - Part 2</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax - Part 2</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 - Part 2</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>T1/2 was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F - Part 2</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>CL/F was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F - Part 2</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vz/F was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Part 1 - Cohort 1: P. vivax: KAF156 400mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Cohort 2: P. falciparum: KAF156 400mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Cohort 3: P. falciparum: KAF156 800mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAF156</intervention_name>
    <description>KAF156 was supplied as tablets for oral use.</description>
    <arm_group_label>Part 1 - Cohort 1: P. vivax: KAF156 400mg QD</arm_group_label>
    <arm_group_label>Part 1 - Cohort 2: P. falciparum: KAF156 400mg QD</arm_group_label>
    <arm_group_label>Part 2 - Cohort 3: P. falciparum: KAF156 800mg single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Male and female patients aged 20 to 60 years;Presence of mono-infection of P. falciparum
        or P. vivax; Weight between 40 kg to 90 kg.

        Exclusion Criteria:

          -  Patients with signs and symptoms of severe/complicated malaria

          -  Infection with more than one parasite species

          -  Women of child-bearing potential; pregnant or nursing women

          -  Those who have taken any anti-malarial treatment in the preceding 14 days or other
             investigational drugs within 30 days or 5 half-lives
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Srisaket</city>
        <zip>33140</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tak</city>
        <zip>63110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tak</city>
        <zip>63140</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hanoi</city>
        <zip>10000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 1, 2015</lastchanged_date>
  <firstreceived_date>December 17, 2012</firstreceived_date>
  <firstreceived_results_date>July 23, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute malaria, KAF156</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Vivax</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The enrollment of P. vivax malaria patients (Cohort 1) began first. Then the falciparum cohort began enrollment after four vivax patients had completed their dosing. Cohort 3 was enrolled after the completion of an interim analysis of safety, tolerability and efficacy data of seven completed patients in the second cohort of Part 1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD</title>
          <description>Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.</description>
        </group>
        <group group_id="P2">
          <title>Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD</title>
          <description>Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.</description>
        </group>
        <group group_id="P3">
          <title>Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose</title>
          <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacodynamic (PD) Set</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacokinetic(PK) Set</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-treat Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD</title>
          <description>Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.</description>
        </group>
        <group group_id="B2">
          <title>Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD</title>
          <description>Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.</description>
        </group>
        <group group_id="B3">
          <title>Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose</title>
          <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="22"/>
                <measurement group_id="B4" value="43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="28.1" spread="8.42"/>
                <measurement group_id="B2" value="36.7" spread="10.90"/>
                <measurement group_id="B3" value="28.9" spread="7.00"/>
                <measurement group_id="B4" value="31.2" spread="8.77"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>Males only</description>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="22"/>
                <measurement group_id="B4" value="43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Parasite Clearance</title>
        <description>Parasite clearance was determined by assessing the parasite count in blood, using thin film, thick film and blood density assessments.</description>
        <time_frame>Day 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic (PD) analysis set for Cohorts 1, 2 and 3: The PD set included all participants who received at least one dose of study medication except for 1 participant from Cohort 1, who was excluded due to a protocol deviation, and 1 participant from Cohort 3, who was withdrawn on Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD</title>
            <description>Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD</title>
            <description>Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose</title>
            <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Parasite Clearance</title>
            <description>Parasite clearance was determined by assessing the parasite count in blood, using thin film, thick film and blood density assessments.</description>
            <units>Hours</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23.63" lower_limit="16.00" upper_limit="30.02"/>
                  <measurement group_id="O2" value="44.97" lower_limit="36.25" upper_limit="47.98"/>
                  <measurement group_id="O3" value="48.75" lower_limit="42.00" upper_limit="53.95"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>28-day Cure Rate - Part 2</title>
        <description>28-day cure rate was defined as the percentage of participants with blood parasite count of zero after 28 days of treatment.</description>
        <time_frame>Day 28</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat analysis set: the intent-to-treat analysis set included all randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose</title>
            <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>28-day Cure Rate - Part 2</title>
            <description>28-day cure rate was defined as the percentage of participants with blood parasite count of zero after 28 days of treatment.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="63.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC)0-24h - Part 1</title>
        <description>AUC0-24h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose was taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
        <time_frame>Days 1 and 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set for Cohorts 1 and 2: The PK set included all participants who received at least one dose of study medication except for 1 participant from Cohort 1, who was excluded due to a protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD</title>
            <description>Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD</title>
            <description>Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Curve (AUC)0-24h - Part 1</title>
            <description>AUC0-24h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose was taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
            <units>(hr*ng/mL)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9470" spread="2140"/>
                  <measurement group_id="O2" value="10100" spread="2440"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20200" spread="3730"/>
                  <measurement group_id="O2" value="21700" spread="6630"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax) - Part 1</title>
        <description>Cmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
        <time_frame>Days 1 and 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set for Cohorts 1 and 2: The PK set included all participants who received at least one dose of study medication except for 1 participant from Cohort 1, who was excluded due to a protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD</title>
            <description>Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD</title>
            <description>Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Concentration (Cmax) - Part 1</title>
            <description>Cmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
            <units>ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="795" spread="182"/>
                  <measurement group_id="O2" value="856" spread="158"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1440" spread="299"/>
                  <measurement group_id="O2" value="1620" spread="384"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Concentration (Tmax) - Part 1</title>
        <description>Tmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
        <time_frame>Days 1 and 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set for Cohorts 1 and 2: The PK set included all participants who received at least one dose of study medication except for 1 participant from Cohort 1, who was excluded due to a protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD</title>
            <description>Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD</title>
            <description>Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Maximum Concentration (Tmax) - Part 1</title>
            <description>Tmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
            <units>hour</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="6.00"/>
                  <measurement group_id="O2" value="3.00" lower_limit="1.00" upper_limit="4.03"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="5.98"/>
                  <measurement group_id="O2" value="2.52" lower_limit="2.00" upper_limit="3.02"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC)Last - Part 1</title>
        <description>AUClast was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
        <time_frame>Day 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set for Cohorts 1 and 2: The PK set included all participants who received at least one dose of study medication except for 1 participant from Cohort 1, who was excluded due to a protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD</title>
            <description>Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD</title>
            <description>Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Curve (AUC)Last - Part 1</title>
            <description>AUClast was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
            <units>hr*ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="55800" spread="12800"/>
                  <measurement group_id="O2" value="54300" spread="22500"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC)Inf - Part 1</title>
        <description>AUCinf was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
        <time_frame>Day 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set for Cohorts 1 and 2: The PK set included all participants who received at least one dose of study medication except for 1 participant from Cohort 1, who was excluded due to a protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD</title>
            <description>Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD</title>
            <description>Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Curve (AUC)Inf - Part 1</title>
            <description>AUCinf was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
            <units>hr*ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58300" spread="14500"/>
                  <measurement group_id="O2" value="56700" spread="24800"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life (T1/2) - Part 1</title>
        <description>T1/2 was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
        <time_frame>Day 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set for Cohorts 1 and 2: The PK set included all participants who received at least one dose of study medication except for 1 participant from Cohort 1, who was excluded due to a protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD</title>
            <description>Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD</title>
            <description>Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Half-life (T1/2) - Part 1</title>
            <description>T1/2 was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
            <units>hr</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39.0" spread="7.40"/>
                  <measurement group_id="O2" value="40.8" spread="8.37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (CL/F ) - Part 1</title>
        <description>CL/F was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
        <time_frame>Day 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set for Cohorts 1 and 2: The PK set included all participants who received at least one dose of study medication except for 1 participant from Cohort 1, who was excluded due to a protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD</title>
            <description>Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD</title>
            <description>Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clearance (CL/F ) - Part 1</title>
            <description>CL/F was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
            <units>L/hr</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20.4" spread="4.04"/>
                  <measurement group_id="O2" value="19.7" spread="5.12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F) - Part 1</title>
        <description>Vz/F was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
        <time_frame>Day 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set for Cohorts 1 and 2: The PK set included all participants who received at least one dose of study medication except for 1 participant from Cohort 1, who was excluded due to a protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD</title>
            <description>Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD</title>
            <description>Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F) - Part 1</title>
            <description>Vz/F was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
            <units>Liters</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1150" spread="286"/>
                  <measurement group_id="O2" value="1140" spread="288"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratio (Racc) (=AUC0-24h, day3/AUC0-24h, day1) - Part 1</title>
        <description>Racc was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
        <time_frame>Day 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set for Cohorts 1 and 2: The PK set included all participants who received at least one dose of study medication except for 1 participant from Cohort 1, who was excluded due to a protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD</title>
            <description>Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD</title>
            <description>Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Accumulation Ratio (Racc) (=AUC0-24h, day3/AUC0-24h, day1) - Part 1</title>
            <description>Racc was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
            <units>ratio</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.16" spread="0.256"/>
                  <measurement group_id="O2" value="2.15" spread="0.384"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-24h - Part 2</title>
        <description>AUC0-24h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.</description>
        <time_frame>Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set analysis set for Cohort 3: The PK set for Cohort 3 included participants who received at least one dose of study medication except for 1 participant who was withdrawn on Day 1 and 3 participants who vomited before 3 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose</title>
            <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC0-24h - Part 2</title>
            <description>AUC0-24h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.</description>
            <units>hr*ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21700" spread="5680"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-48h - Part 2</title>
        <description>AUC0-48h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
        <time_frame>Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set analysis set for Cohort 3: The PK set for Cohort 3 included participants who received at least one dose of study medication except for 1 participant who was withdrawn on Day 1 and 3 participants who vomited before 3 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose</title>
            <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC0-48h - Part 2</title>
            <description>AUC0-48h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
            <units>hr*ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33600" spread="9150"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUClast - Part 2</title>
        <description>AUClast was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
        <time_frame>Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set analysis set for Cohort 3: The PK set for Cohort 3 included participants who received at least one dose of study medication except for 1 participant who was withdrawn on Day 1 and 3 participants who vomited before 3 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose</title>
            <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUClast - Part 2</title>
            <description>AUClast was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
            <units>hr*ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="54900" spread="16600"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCinf - Part 2</title>
        <description>AUCinf was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
        <time_frame>Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set analysis set for Cohort 3: The PK set for Cohort 3 included participants who received at least one dose of study medication except for 1 participant who was withdrawn on Day 1 and 3 participants who vomited before 3 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose</title>
            <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUCinf - Part 2</title>
            <description>AUCinf was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
            <units>hr*ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58300" spread="18600"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax - Part 2</title>
        <description>Cmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.</description>
        <time_frame>Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set analysis set for Cohort 3: The PK set for Cohort 3 included participants who received at least one dose of study medication except for 1 participant who was withdrawn on Day 1 and 3 participants who vomited before 3 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose</title>
            <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cmax - Part 2</title>
            <description>Cmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.</description>
            <units>ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1800" spread="404"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax - Part 2</title>
        <description>Tmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.</description>
        <time_frame>Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set analysis set for Cohort 3: The PK set for Cohort 3 included participants who received at least one dose of study medication except for 1 participant who was withdrawn on Day 1 and 3 participants who vomited before 3 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose</title>
            <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tmax - Part 2</title>
            <description>Tmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.</description>
            <units>hours</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.52" lower_limit="2.00" upper_limit="11.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2 - Part 2</title>
        <description>T1/2 was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
        <time_frame>Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set analysis set for Cohort 3: The PK set for Cohort 3 included participants who received at least one dose of study medication except for 1 participant who was withdrawn on Day 1 and 3 participants who vomited before 3 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose</title>
            <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>T1/2 - Part 2</title>
            <description>T1/2 was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
            <units>hours</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48.7" spread="7.85"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F - Part 2</title>
        <description>CL/F was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
        <time_frame>Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set analysis set for Cohort 3: The PK set for Cohort 3 included participants who received at least one dose of study medication except for 1 participant who was withdrawn on Day 1 and 3 participants who who vomited before 3 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose</title>
            <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>CL/F - Part 2</title>
            <description>CL/F was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
            <units>L/hr</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15.1" spread="4.85"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz/F - Part 2</title>
        <description>Vz/F was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
        <time_frame>Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) analysis set analysis set for Cohort 3: The PK set for Cohort 3 included participants who received at least one dose of study medication except for 1 participant who was withdrawn on Day 1 and 3 participants who vomited before 3 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose</title>
            <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Vz/F - Part 2</title>
            <description>Vz/F was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.</description>
            <units>Liters</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1030" spread="264"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD</title>
          <description>Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.</description>
        </group>
        <group group_id="E2">
          <title>Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD</title>
          <description>Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.</description>
        </group>
        <group group_id="E3">
          <title>Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose</title>
          <description>Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Monocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Monocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thyroxine free increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
